What is the half-life of Retatrutide?

Retatrutide has a long half-life with gradual onset characteristics in published research.

What is Retatrutide researched for?

Retatrutide is studied in the following research areas: Energy regulation, Metabolic signalling, Hormonal interaction.

METABOLIC RESEARCHRTA

Retatrutide

A multi-receptor research peptide studied for metabolic signalling, energy regulation, and hormonal interaction across long-duration research models.

Half-Life

Long

Onset

Gradual

Symbol

RTA

Long duration profile

Retatrutide demonstrates a long half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Gradual measurable response

Onset is observed as gradual — a property that influences how researchers structure comparative studies versus other compounds in the metabolic research category.

🧠 Key Notes

What makes it distinct

01High research interest in 2025–2026
02Multi-target receptor interaction profile
03Suitable for long-duration observational studies

🧬 Mechanism of Action

How it works

Retatrutide is a synthetic triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors. GLP-1 activation enhances glucose-dependent insulin release and slows gastric emptying, GIP activation amplifies post-prandial insulin response and modulates adipose lipid handling, and glucagon receptor activation increases basal energy expenditure and hepatic lipid oxidation. The combined signalling produces broader metabolic effects than mono- or dual-agonists like semaglutide or tirzepatide, addressing both intake (appetite, satiety) and output (energy expenditure) sides of the energy balance equation.

✨ Documented Benefits

What the research shows it supports

B01Substantial reductions in body weight and visceral adiposity in Phase II trials — among the largest effect sizes recorded for a metabolic peptide.

B02Improved glycaemic control and insulin sensitivity in research populations with insulin resistance.

B03Increased basal energy expenditure via glucagon-receptor activation, distinguishing it from GLP-1-only agonists.

B04Once-weekly dosing schedules in published protocols, simplifying long-duration study design.

🔍 Research Insights

What the literature shows

INSIGHT 01

Acts simultaneously on GLP-1, GIP, and glucagon receptors — a triple-agonist profile that distinguishes it from earlier mono- or dual-agonist peptides.

INSIGHT 02

Long half-life supports once-weekly dosing models in published trials, simplifying compliance variables in study design.

INSIGHT 03

Phase II data has shown some of the largest weight-reduction effect sizes recorded in metabolic peptide literature to date.

🧪 Typical Research Use Cases

Where it appears in study design

USE CASE 01

Comparative metabolic studies versus tirzepatide and semaglutide.

USE CASE 02

Long-duration energy expenditure and adipose modelling.

USE CASE 03

Glucose homeostasis research in insulin-resistant models.

🔬 Study Deep Dive

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial

Jastreboff AM, et al. · New England Journal of Medicine · 2023

Design

48-week, randomised, double-blind, placebo-controlled phase 2 trial.

Population

338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related complication.

Intervention

Weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) titrated versus placebo.

Primary Finding

Mean weight change at week 48 was −24.2% in the 12 mg cohort vs −2.1% for placebo — the largest weight reduction reported for a metabolic peptide in a phase 2 setting.

TAKEAWAY

Triple agonism (GLP-1 + GIP + glucagon) produced dose-dependent reductions in both adiposity and metabolic markers beyond dual-agonist benchmarks.

Read the full study ↗

📚 References

Peer-reviewed literature

Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.

[01]
Jastreboff, A. M. et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526.
New England Journal of Medicine ↗
[02]
Rosenstock, J. et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet, 402(10401), 529–544.
The Lancet ↗
[03]
Sanyal, A. J. et al. (2024). Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction–Associated Steatotic Liver Disease. Nature Medicine, 30, 2037–2048.
Nature Medicine ↗
[04]
Coskun, T. et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.
Cell Metabolism ↗

⚠️ Not Medical Advice

Educational research summary only

This profile summarises published research on Retatrutide. It is not medical advice, diagnosis, or treatment, and it is not intended to promote human use, self-administration, or the substitution of professional healthcare. Discuss any health decision with a licensed clinician.

Continue Exploring

Also explore: MOTS-c, Semax, GHK-Cu, 5-Amino-1MQ

MOTS-c →Semax →GHK-Cu →5-Amino-1MQ →Half-Life Guide →Metabolic Research →